ID   YCU-AML2
AC   CVCL_E7AL
SY   Yokohama City University-Acute Myeloid Leukemia 2
RX   PubMed=39891826;
CC   Population: Japanese.
CC   Doubling time: 3-4 days (PubMed=39891826).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=39891826).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=39891826).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7132; KMT2A + HGNC; HGNC:7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9; Note=KMT2A intron 8 fused to MLLT3 intron 4 (PubMed=39891826).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (PubMed=39891826).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9163; Childhood acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   5Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=39891826; DOI=10.1007/s12185-025-03929-x;
RA   Ikeda J., Shiba N., Kato S., Kunimoto H., Saito Y., Sagisaka M., Ito M.,
RA   Goto H., Okuno Y., Nakamura W., Yoshitomi M., Takeuchi M., Ito S.,
RA   Nakajima H., Kato M., Tsujimoto S.-i.;
RT   "Establishment of a high-risk pediatric AML-derived cell line YCU-AML2
RT   with genetic and metabolic vulnerabilities.";
RL   Int. J. Hematol. 0:0-0(2025).
//